Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MODD NYSE:QHC NYSE:SSY NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMODDModular Medical$0.75-0.3%$0.72$0.63▼$2.50$41.33M0.17227,211 shs1.24 million shsQHCQuorum Health$0.30$0.37$0.22▼$2.49$10.01M2.29266,388 shsN/ASSYSunLink Health Systems$1.12+16.6%$1.10$0.62▼$1.91$7.88M1.16145,367 shs243,934 shsTELOTelomir Pharmaceuticals$1.33-2.2%$1.55$1.12▼$8.40$42.93M-0.721.76 million shs422,015 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMODDModular Medical0.00%+4.70%+4.18%-5.22%-67.81%QHCQuorum Health0.00%0.00%0.00%0.00%0.00%SSYSunLink Health Systems0.00%0.00%0.00%+13.60%+43.46%TELOTelomir Pharmaceuticals0.00%+9.68%-8.72%-32.00%-77.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMODDModular Medical$0.75-0.3%$0.72$0.63▼$2.50$41.33M0.17227,211 shs1.24 million shsQHCQuorum Health$0.30$0.37$0.22▼$2.49$10.01M2.29266,388 shsN/ASSYSunLink Health Systems$1.12+16.6%$1.10$0.62▼$1.91$7.88M1.16145,367 shs243,934 shsTELOTelomir Pharmaceuticals$1.33-2.2%$1.55$1.12▼$8.40$42.93M-0.721.76 million shs422,015 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMODDModular Medical0.00%+4.70%+4.18%-5.22%-67.81%QHCQuorum Health0.00%0.00%0.00%0.00%0.00%SSYSunLink Health Systems0.00%0.00%0.00%+13.60%+43.46%TELOTelomir Pharmaceuticals0.00%+9.68%-8.72%-32.00%-77.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMODDModular Medical 0.00N/AN/AN/AQHCQuorum Health 0.00N/AN/AN/ASSYSunLink Health Systems 0.00N/AN/AN/ATELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,027.82% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMODDModular MedicalN/AN/AN/AN/A$0.42 per shareN/AQHCQuorum Health$1.88B0.01$0.66 per share0.46($2.38) per share-0.13SSYSunLink Health Systems$31.09M0.25N/AN/A$2.27 per share0.49TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMODDModular Medical-$18.82M-$0.51N/A∞N/AN/A-185.60%-158.95%11/12/2025 (Estimated)QHCQuorum Health-$200.25MN/AN/A∞N/A-8.65%N/A-4.00%N/ASSYSunLink Health Systems-$1.53M$0.244.66∞N/A5.55%-18.98%-14.79%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest QHC, SSY, MODD, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q1 2026MODDModular Medical-$0.10-$0.12-$0.02-$0.12$0.20 millionN/A8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/A6/20/2025Q4 2025MODDModular Medical-$0.11-$0.12-$0.01-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMODDModular MedicalN/AN/AN/AN/AN/AQHCQuorum HealthN/AN/AN/AN/AN/ASSYSunLink Health SystemsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ALatest QHC, SSY, MODD, and TELO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/18/2025SSYSunLink Health Systemsspecial$0.107/31/20257/29/20257/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMODDModular MedicalN/A4.044.04QHCQuorum HealthN/A1.211.10SSYSunLink Health SystemsN/A3.913.50TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMODDModular Medical27.47%QHCQuorum Health58.36%SSYSunLink Health Systems23.67%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipMODDModular Medical20.46%QHCQuorum Health6.10%SSYSunLink Health Systems27.90%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMODDModular Medical2055.28 million43.97 millionNot OptionableQHCQuorum Health11,60032.92 millionN/AOptionableSSYSunLink Health Systems1,3767.04 million5.08 millionNot OptionableTELOTelomir Pharmaceuticals132.28 millionN/AN/AQHC, SSY, MODD, and TELO HeadlinesRecent News About These CompaniesTELO Releases Cancer Suppressing ResultsSeptember 9, 2025 | msn.comTelomir Pharmaceuticals announces preclinical cancer data on Telomir-1September 9, 2025 | msn.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor ...September 9, 2025 | charlotteobserver.comCTelomir Pharmaceuticals Unveils Promising Preclinical Cancer DataSeptember 9, 2025 | tipranks.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapySeptember 9, 2025 | accessnewswire.comATelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest UpdateSeptember 8, 2025 | americanbankingnews.comTelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4, 2025 | tipranks.comTelomir stock soars after drug candidate shows promising epigenetic effectsAugust 28, 2025 | za.investing.comTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...August 28, 2025 | kansascity.comKTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesAugust 28, 2025 | accessnewswire.comATELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir-1 inhibits key histone demethylase enzymes in vitroAugust 12, 2025 | bioworld.comBTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...August 8, 2025 | kansascity.comKTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionAugust 7, 2025 | accessnewswire.comATelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comTELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sJuly 24, 2025 | accessnewswire.comATelomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer ResultsJuly 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQHC, SSY, MODD, and TELO Company DescriptionsModular Medical NASDAQ:MODD$0.75 0.00 (-0.31%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.03 (-4.24%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.Quorum Health NYSE:QHCQuorum Health Corporation, together with its subsidiaries, provides hospital and outpatient healthcare services in the United States. Its hospital and outpatient healthcare services include general and acute care, emergency room, general and specialty surgery, critical care, internal medicine, diagnostic, obstetric, psychiatric, and rehabilitation services. Quorum Health Corporation offers its healthcare services through its hospitals and affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics, and surgery centers. The company, through its subsidiary, Quorum Health Resources, LLC, provides hospital management advisory, healthcare consulting, and group purchasing services to non-affiliated hospitals, as well as Web-based applications and software tools; and various education programs for healthcare leaders, professionals, and other medical staff. As of December 31, 2018, it owned or leased 27 hospitals with approximately 2,604 licensed beds. The company was incorporated in 2015 and is headquartered in Brentwood, Tennessee.SunLink Health Systems NYSE:SSY$1.12 +0.16 (+16.56%) Closing price 08/14/2025Extended Trading$1.12 0.00 (0.00%) As of 08/14/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SunLink Health Systems, Inc., through its subsidiaries, provides healthcare products and services in the southeastern United States. It operates in two segments, Healthcare Services and Pharmacy. The Healthcare Services segment owns and operates a 49-licensed-bed acute care hospital, which includes a 26-bed geriatric psychiatry unit; two clinics; and a 66-bed extended care and rehabilitation centre. This segment also provides information technology services; and owns five acers unimproved lands. The Pharmacy segment offers institutional pharmacy services consisting of provision of specialty and non-specialty pharmaceutical and biological products, such as nursing homes, assisted living facilities, behavioural and specialty hospitals, hospices, and correctional facilities; non-institutional pharmacy services, including private residences; and durable medical equipment products and services, including the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care, as well as retails pharmacy products and services. SunLink Health Systems, Inc. was incorporated in 1959 and is based in Atlanta, Georgia.Telomir Pharmaceuticals NASDAQ:TELO$1.33 -0.03 (-2.21%) Closing price 04:00 PM EasternExtended Trading$1.29 -0.04 (-3.01%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
